1. Home
  2. PRTA vs ADV Comparison

PRTA vs ADV Comparison

Compare PRTA & ADV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Prothena Corporation plc

PRTA

Prothena Corporation plc

N/A

Current Price

$8.36

Market Cap

458.4M

Sector

Health Care

ML Signal

N/A

Logo Advantage Solutions Inc.

ADV

Advantage Solutions Inc.

N/A

Current Price

$33.55

Market Cap

523.2M

ML Signal

N/A

Company Overview

Basic Information
Metric
PRTA
ADV
Founded
2012
1987
Country
Ireland
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Business Services
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
458.4M
523.2M
IPO Year
2013
2019

Fundamental Metrics

Financial Performance
Metric
PRTA
ADV
Price
$8.36
$33.55
Analyst Decision
Buy
Strong Buy
Analyst Count
9
3
Target Price
$19.00
$45.83
AVG Volume (30 Days)
307.4K
57.0K
Earning Date
05-07-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.26
N/A
Revenue
$814,000.00
$3,542,642,000.00
Revenue This Year
$1,111.38
$0.63
Revenue Next Year
N/A
$0.45
P/E Ratio
$34.35
N/A
Revenue Growth
N/A
N/A
52 Week Low
$7.73
$0.49
52 Week High
$11.80
$47.45

Technical Indicators

Market Signals
Indicator
PRTA
ADV
Relative Strength Index (RSI) 42.61 49.96
Support Level $8.62 $33.26
Resistance Level $9.36 $35.50
Average True Range (ATR) 0.33 1.74
MACD -0.08 0.23
Stochastic Oscillator 8.60 65.29

Price Performance

Historical Comparison
PRTA
ADV

About PRTA Prothena Corporation plc

Prothena Corp PLC is a late-stage clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. Prothena is developing and applying its proprietary CYTOPE technology to target a broad spectrum of intracellular disease pathways in the brain and periphery. The company's pipeline includes both wholly-owned and partnered programs like Prasinezumab, Coramitug (PRX004), BMS-986446 (PRX005), PRX019, TDP-43 CYTOPE, and PRX012-TfR, being developed for the potential treatment of Parkinson's disease, ATTR amyloidosis with cardiomyopathy, Alzheimer's disease, Amyotrophic lateral sclerosis (ALS), and other neurodegenerative diseases.

About ADV Advantage Solutions Inc.

Advantage Solutions Inc provides outsourced sales, marketing, merchandising, sampling, and retailer support services to consumer packaged goods manufacturers and retailers across North America. Its services are designed to support distribution, retail execution, shopper engagement, and private brand development across both physical and digital commerce environments. The company serves various clients across grocery, mass, club, retail pharmacy, convenience, and other channels. It operates through three reportable segments: Branded Services, Experiential Services, and Retailer Services. The majority of the revenue is derived from the Experiential Services segment, which provides in-store and digital sampling programs, demonstrations, and experiential events for manufacturers and retailers.

Share on Social Networks: